Abstract:The process of cellular senescence, which is characterized by stable cell cycle arrest, is strongly associated with dysfunctional cellular metabolism and circadian rhythmicity, both of which are reported to result from and also be causal to cellular senescence. As a result, modifying any of them—senescence, metabolism, or the circadian clock—may affect all three simultaneously. Obesity accelerates aging by disrupting the homeostasis of reactive oxygen species (ROS) via an increased mitochondrial burden of fatty acid oxidation. As a result, if senescence, metabolism, and circadian rhythm are all linked, anti-obesity treatments may improve metabolic regulation while also alleviating senescence and circadian rhythm. Vutiglabridin is a small molecule in clinical trials that improves obesity by enhancing mitochondrial function. We found that chronic treatment of senescent primary human dermal fibroblasts (HDFs) with vutiglabridin alleviates all investigated markers of cellular senescence (SA-β-gal, CDKN1A, CDKN2A) and dysfunctional cellular circadian rhythm (BMAL1) while remarkably preventing the alterations of mitochondrial function and structure that occur during the process of cellular senescence. Our results demonstrate the significant senescence-alleviating effects of vutiglabridin, specifically with the restoration of cellular circadian rhythmicity and metabolic regulation. These data support the potential development of vutiglabridin against aging-associated diseases and corroborate the intricate link between cellular senescence, metabolism, and the circadian clock.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is the problems of metabolic dysfunction and circadian rhythm disorder during cellular senescence. Specifically, the researchers focused on whether the small - molecule drug Vutiglabridin can relieve cellular senescence, abnormal metabolic regulation and circadian rhythm disorder in human dermal fibroblasts (HDFs) by improving mitochondrial function. The paper experimentally verified the effect of Vutiglabridin on high - passage - number HDFs under chronic treatment, and found that Vutiglabridin can significantly reduce the aging markers (such as SA - β - gal, CDKN1A, CDKN2A) of these cells, restore the circadian rhythm of the cells, and prevent changes in mitochondrial function and structure. This indicates that Vutiglabridin may become an effective means to combat aging - related diseases.

Vutiglabridin Alleviates Cellular Senescence with Metabolic Regulation and Circadian Clock in Human Dermal Fibroblasts